The study has been made possible due to Salford’s electronic health medical records (EHR) system, which links patient records across GP surgeries and hospitals. GSK worked with the city’s pharmacies to also link them to the system, allowing comprehensive monitoring of patients in the study with minimal intrusion into their everyday lives.
The EHR system has created a unique medical infrastructure. The system was enhanced to capture health resource utilisation and outcome data. A platform was also developed to monitor patients, providing near-real time safety monitoring and reporting. This enhancement was built by NorthWest EHealth, a not for profit organisation formed by a partnership between The University of Manchester, Salford Royal Foundation Trust and Salford Clinical Commissioning Group. The EHR was a key reason for locating SLS in Salford.
A further unique collaboration that GSK has formed in designing the Salford Lung Study is with the UK Medicines and Healthcare Products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE) from whom we sought advice when designing the study.
The study has involved collaboration with thousands of patients, healthcare professionals and academics in the city of Salford, UK, providing an opportunity for many healthcare professionals to be involved in clinical research for the first time. More than 3000 people were trained as part of the study team, leaving a legacy for Salford as a unique research city, while creating data that can be generalised to patients world-wide.